Technical Analysis for MNOV - MediciNova, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
50 DMA Resistance | Bearish | 0.00% | |
Fell Below 20 DMA | Bearish | 3.85% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -0.74% | |
Crossed Above 20 DMA | Bullish | -0.74% | |
Inside Day | Range Contraction | -0.74% | |
50 DMA Resistance | Bearish | 0.00% | |
Fell Below 20 DMA | Bearish | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
Outside Day | Range Expansion | 0.00% |
Alert | Time |
---|---|
Rose Above 50 DMA | about 17 hours ago |
50 DMA Resistance | about 18 hours ago |
60 Minute Opening Range Breakout | about 22 hours ago |
10 DMA Resistance | about 22 hours ago |
Rose Above Previous Day's High | about 23 hours ago |
Get a Trading Sidekick!
- Earnings date: 02/14/2024
MediciNova, Inc. Description
MediciNova, Inc., a development stage biopharmaceutical company, focuses on acquiring and developing small molecule therapeutics for the treatment of serious diseases for the United States market. The company's principal product candidates include MN-166, an ibudilast-based drug candidate, which is in Phase I and Phase II clinical trials for the treatment of drug dependence and pain; and MN-221, a ß2 -adrenergic receptor agonist that has completed Phase II clinical trials for the treatment of acute exacerbations of asthma. It also has other product candidates in the clinical development for the treatment of acute exacerbations of asthma, multiple sclerosis and other central nervous system disorders, bronchial asthma, interstitial cystitis, solid tumor cancers, generalized anxiety disorders/insomnia, preterm labor, urinary incontinence, and thrombotic disorders. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pain Clinical Development Medication Central Nervous System Disorders Asthma Respiratory Therapy Multiple Sclerosis Nervous System Disorders Solid Tumor Cancers Pulmonology Insomnia Molecule Therapeutics Urinary Incontinence Interstitial Cystitis Bronchial Asthma
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.66 |
52 Week Low | 1.26 |
Average Volume | 50,998 |
200-Day Moving Average | 1.92 |
50-Day Moving Average | 1.41 |
20-Day Moving Average | 1.35 |
10-Day Moving Average | 1.37 |
Average True Range | 0.07 |
RSI (14) | 47.09 |
ADX | 13.75 |
+DI | 15.57 |
-DI | 17.11 |
Chandelier Exit (Long, 3 ATRs) | 1.22 |
Chandelier Exit (Short, 3 ATRs) | 1.48 |
Upper Bollinger Bands | 1.42 |
Lower Bollinger Band | 1.28 |
Percent B (%b) | 0.49 |
BandWidth | 10.72 |
MACD Line | -0.02 |
MACD Signal Line | -0.02 |
MACD Histogram | 0.0025 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.52 | ||||
Resistance 3 (R3) | 1.52 | 1.47 | 1.49 | ||
Resistance 2 (R2) | 1.47 | 1.43 | 1.47 | 1.48 | |
Resistance 1 (R1) | 1.41 | 1.40 | 1.44 | 1.41 | 1.47 |
Pivot Point | 1.36 | 1.36 | 1.38 | 1.36 | 1.36 |
Support 1 (S1) | 1.30 | 1.32 | 1.33 | 1.30 | 1.23 |
Support 2 (S2) | 1.25 | 1.29 | 1.25 | 1.22 | |
Support 3 (S3) | 1.19 | 1.25 | 1.21 | ||
Support 4 (S4) | 1.19 |